Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses

References

• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in crohn’s disease: medical treatment. J Crohns Colitis. 2020;14(2):155–168. doi: 10.1093/ecco-jcc/jjz187.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Isaacs KL, Schneider Y ; AGA Institute Clinical Guidelines Committee, et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1450–1461. doi: 10.1053/j.gastro.2020.01.006.
   PubMed Web of Science ®Google Scholar
• Feuerstein JD, Ho EY, Shmidt E; American Gastroenterological Association Institute Clinical Guidelines Committee, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing crohn’s disease. Gastroenterology. 2021;160(7):2496–2508. doi: 10.1053/j.gastro.2021.04.022.
   PubMed Web of Science ®Google Scholar
• Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022;16(1):2–17. doi: 10.1093/ecco-jcc/jjab178.
   PubMed Web of Science ®Google Scholar
• Ebada MA, Elmatboly AM, Ali AS, et al. An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease. Int J Colorectal Dis. 2019;34(10):1633–1652. doi: 10.1007/s00384-019-03354-7.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340–2353. doi: 10.1053/j.gastro.2021.02.068.
   PubMed Web of Science ®Google Scholar
• Smith PJ, Critchley L, Storey D, et al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: A multicentre cohort study. J Crohns Colitis. 2022;16(9):1436–1446. doi: 10.1093/ecco-jcc/jjac053.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients With ulcerative colitis. Gastroenterology. 2020;158(3):562–572.e12. doi: 10.1053/j.gastro.2019.08.027.
   PubMed Web of Science ®Google Scholar
• Vermeire S, D’Haens G, Baert F, et al. Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active crohn’s disease: results From the VISIBLE 2 randomised trial. J Crohns Colitis. 2022;16(1):27–38. doi: 10.1093/ecco-jcc/jjab133.
   PubMed Web of Science ®Google Scholar
• Shirley M. Subcutaneous infliximab, CT-P13 SC: a profile of its use in the EU. Clin Drug Investig. 2021;41(12):1099–1107. doi: 10.1007/s40261-021-01093-8.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Remsima summary of product characteristics. Available from: https://www.ema. europa.eu/en/documents/product-information/remsimaJune 2021 CT-P13 SC vs CT-P13 IV in Patients With IBD 2351 CLINICAL AT epar-product-information_en.pdf. 2020.
   Google Scholar
• Vedolizumab. Summary of product characteristics. Taastrup: Takeda Pharma A/S; 2020.
   Google Scholar
• Yoo HK, Byun HG, Caprioli F, et al. Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the big-5 european (E5) countries. BMC Health Serv Res. 2022;22(1):1319. doi: 10.1186/s12913-022-08683-y.
   PubMed Web of Science ®Google Scholar
• Oppe M, Muresan B, Chan K, et al. Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France. Expert Rev Pharmacoecon Outcomes Res. 2023;23(2):205–213. doi: 10.1080/14737167.2023.2160322.
   PubMed Web of Science ®Google Scholar
• Remy C, Caron B, Gouynou C, et al. Inflammatory bowel disease patients’ acceptance for switching from intravenous infliximab or vedolizumab to subcutaneous formulation: the nancy experience. J Clin Med. 2022;11(24):7296. doi: 10.3390/jcm11247296.
   PubMed Web of Science ®Google Scholar
• Volkers A, Straatmijer T, Duijvestein M, et al. IBD center amsterdam and the dutch initiative on crohn and colitis. Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;56(6):1044–1054. doi: 10.1111/apt.17153.
   PubMed Web of Science ®Google Scholar
• Bergqvist V, Holmgren J, Klintman D, et al. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2022;55(11):1389–1401. doi: 10.1111/apt.16927.
   PubMed Web of Science ®Google Scholar
• Smith PJ, Fumery M, Leong RW, et al. Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease. Expert Rev Clin Immunol. 2023;19(9):1143–1156. doi: 10.1080/1744666X.2023.2231148.
   PubMed Web of Science ®Google Scholar
• Puolanne AM, Kolho KL, Alfthan H, et al. Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic inflammatory bowel disease. Dig Dis Sci. 2017;62(11):3123–3130. doi: 10.1007/s10620-017-4770-0.
   PubMed Web of Science ®Google Scholar
• Moore C, Corbett G, Moss AC. Systematic review and Meta-Analysis: serum infliximab levels during maintenance therapy and outcomes in inflammatory bowel disease. J Crohns Colitis. 2016;10(5):619–625. doi: 10.1093/ecco-jcc/jjw007.
   PubMed Web of Science ®Google Scholar
• Borren NZ, Paulides E, Frinack J, et al. Infliximab trough levels are not predictive of relapse in patients with IBD in endoscopic remission: a multicenter cohort study. Dig Dis Sci. 2021;66(10):3548–3554. doi: 10.1007/s10620-020-06645-0.
   PubMed Web of Science ®Google Scholar
• Singh S, Dulai PS, Casteele NV, et al. Systematic review with meta-analysis: association between vedolozumab trough concentration and clinical outcomesin patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(8):848–857. doi: 10.1111/apt.15484.
   PubMed Web of Science ®Google Scholar
• Ungaro RC, Yarur A, Jossen J, et al. Higher trough vedolizumab concentrations during maintenance therapy are associated with Corticosteroid-Free remission in inflammatory bowel disease. J Crohns Colitis. 2019;13(8):963–969. doi: 10.1093/ecco-jcc/jjz041.
   PubMed Web of Science ®Google Scholar
• Strik AS, van de Vrie W, Bloemsaat-Minekus JP, et al. Serum concentrations after switching from originator infliximab to the bioimilar CT-P13 in patients withquiescent inflammatory bowel disease (SECURE): and opne-label, multicentre, phase 4 non-inferiority trial. Lancet Gastroenterol Hepatol. 2018;3(6):404–412. doi: 10.1016/S2468-1253(18)30082-7.
   PubMed Web of Science ®Google Scholar
• Buisson A, Nachury M, Reymond M, et al. Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study. Clin Gastroenterol Hepatol. 2022;S1542–3565(22):00776–00775.
   Google Scholar
• Wiken TH, Høivik ML, Buer L, et al. Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring. Scand J Gastroenterol. 2023;58(8):863–873. doi: 10.1080/00365521.2023.2176252.
   PubMed Web of Science ®Google Scholar